Instructions for use Mebikar IC tablets 0.5 g No. 20
Composition
active ingredient: mebicar;
1 tablet contains Mebicar 500 mg (0.5 g);
excipients: methylcellulose, calcium stearate.
Dosage form
Pills.
Main physicochemical properties: white tablets, flat-cylindrical in shape, with a bevel; on one surface of the tablet there is a trademark of the company, on the other surface of the tablet there is a line.
Pharmacotherapeutic group
Psychostimulants, drugs used for attention deficit hyperactivity disorder (ADHD), and nootropics. Other psychostimulants and nootropics. Mebicar. ATX code N06B X21.
Pharmacological properties
Pharmacodynamics
The active substance of the drug (mebicar) is close in chemical structure to the body's natural metabolites: the mebicar molecule consists of two methylated urea fragments that are part of a bicyclic structure.
Mebikar IS has moderate tranquilizing (anxiolytic) activity, relieves or reduces feelings of anxiety, anxiety, fear, internal emotional tension and irritation. The sedative effect of the drug is not accompanied by muscle relaxation and impaired coordination of movements. The drug does not reduce mental and motor activity, so it can be used during the working day or during study. The drug does not create an elevated mood, a feeling of euphoria. On this basis, Mebikar IS is classified as a daytime tranquilizer. The drug does not exhibit a hypnotic effect, but enhances the effect of hypnotics and improves sleep when it is disturbed.
In addition to the sedative effect, the drug has a nootropic effect. Mebikar IS improves cognitive functions, increases attention and mental performance, without stimulating the symptoms of productive psychopathological disorders, such as delusions, pathological emotional activity.
The drug has antioxidant activity, therefore it acts as a membrane stabilizer, adaptogen, and cerebroprotector in oxidative stress of various origins.
Mebikar IS acts on the activity of the structures of the limbic-reticular complex, in particular on the emotional zones of the hypothalamus, and also affects all 4 main neurotransmitter systems - GABAergic, cholinergic, serotoninergic and adrenergic, which contributes to their balance and integration, but does not have a peripheral adrenonegative effect. The neurotransmitter profile of the drug contains a dopamine-positive component. Mebikar IS exhibits antagonistic activity against the excitation of the adrenergic and glutamatergic systems and enhances the functioning of the inhibitory serotonin and GABAergic mechanisms of the brain. The drug has normastenic properties.
Mebikar IS facilitates nicotine withdrawal.
Pharmacokinetics
When administered orally, bioavailability is 77–80%; up to 40% of Mebicar binds to erythrocytes; the remaining 60% does not bind to blood proteins and is contained in the blood plasma in a free state, due to which Mebicar spreads freely in the body and freely passes through membranes. The maximum concentration of Mebicar in the blood serum is reached in 30 minutes, the high level remains for 3–4 hours, then gradually decreases. Mebicar IS is completely excreted from the body with urine during the day, does not accumulate and is not subject to biochemical transformations in the body.
Indication
Neuroses and neurosis-like conditions accompanied by irritation, emotional lability, feelings of anxiety and fear; to improve the tolerance of neuroleptics or tranquilizers in order to eliminate the somatovegetative and neurological side effects caused by them; cardialgia of various genesis (not associated with ischemic heart disease); to alleviate the course of somatovegetative manifestations in premenstrual syndrome and menopause.
The drug is indicated as a cerebroprotector and adaptogen for emotional and oxidative stress of various origins.
As part of complex therapy for nicotine addiction as a means of reducing the urge to smoke.
Contraindication
Individual hypersensitivity to the components of the drug.
Interaction with other medicinal products and other types of interactions
Mebikar IS can be combined with neuroleptics, tranquilizers (benzodiazepines), hypnotics, antidepressants and psychostimulants.
Application features
The drug should be used with caution in cases of arterial hypotension, liver and kidney dysfunction.
Habituation, dependence, and withdrawal syndrome have not been established when using Mebicar.
Ability to influence reaction speed when driving vehicles or other mechanisms
Caution should be exercised when driving vehicles, as sometimes the use of Mebicar can lead to a decrease in blood pressure.
Use during pregnancy or breastfeeding
Mebikar IS penetrates well into all tissues and body fluids.
The drug should not be used during pregnancy or breastfeeding due to the lack of sufficient data on the safety of Mebicar during this period.
Method of administration and doses
The drug is taken orally, regardless of meals. The dosage depends on the individual characteristics of the patient and the therapeutic purpose of the drug. The usual dose is 500 mg 2–3 times a day. If necessary, the dose can be increased. The maximum single dose is 3 g, the maximum daily dose is 10 g. The duration of the course of treatment is from several days to 2–3 months.
As part of a comprehensive treatment for nicotine addiction, the drug is used at 500–1000 mg 3 times a day daily for 5–6 weeks.
If one or more doses are missed on time, the treatment course should be continued according to the previously prescribed regimen.
Children
The medicine is not intended for use in children.
Overdose
The drug is low-toxic. In case of a significant overdose, side effects may be increased (including allergic reactions, dyspeptic disorders, weakness, temporary decrease in blood pressure and body temperature).
Treatment: it is necessary to wash the stomach and apply generally accepted methods of detoxification.
Adverse reactions
The drug is usually well tolerated.
From the cardiovascular system: rarely - a decrease in blood pressure.
Gastrointestinal: rarely - dyspeptic disorders (including nausea, vomiting, diarrhea). In this case, the dose of the drug should be reduced.
On the part of the respiratory system: rarely - bronchospasm.
Skin and subcutaneous tissue disorders: rarely - allergic reactions (including skin rashes, itching, urticaria, angioedema). In case of an allergic reaction, the drug should be discontinued.
General disorders: rarely - decreased body temperature, weakness, dizziness. In case of a decrease in blood pressure and/or body temperature (body temperature may decrease by 1–1.5 °C), the drug does not need to be discontinued. Blood pressure and body temperature normalize independently.
Expiration date
4 years.
Storage conditions
Store in the original packaging at a temperature not exceeding 25 °C.
Keep out of reach of children.
Packaging
10 tablets in a blister, 2 blisters in a pack.
Vacation category
Without a prescription.
Producer
Additional Liability Company "INTERCHEM".
Location of the manufacturer and its business address
Ukraine, 65025, Odessa, 21st km. Starokyivska Road, 40-A.
